Literature DB >> 20367408

Impact of prostate cancer multifocality on its biology and treatment.

Ferran Algaba1, Rodolfo Montironi.   

Abstract

Any focal therapy requires correct localization of the lesion; consequently, much effort is now devoted to accurate characterization of the spatial distribution of the tumor within the prostate. One of the greatest difficulties in the localization of prostate cancer is its frequent multifocality, but prostate cancer is unifocal in 13% to 43.7% of cases and unilateral in 19.2%. In cases of multifocality, it seems that the index tumor is the biologic driving force behind the malignant potential of prostate cancer. Not only is the Gleason score of the secondary nodes lower than that of the index node, but 80% of the secondary nodes are smaller than 0.5 cc and almost all extraprostatic extensions are associated with the largest cancers. While current evaluation with 12 to 18 core biopsies may be adequate to determine the index lesion, transperineal three-dimensional mapping biopsy of the prostate should be undertaken if greater accuracy is needed.

Entities:  

Mesh:

Year:  2010        PMID: 20367408     DOI: 10.1089/end.2009.0462

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  14 in total

Review 1.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

Review 2.  Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions.

Authors:  Hüseyin Cihan Demirel; John Warren Davis
Journal:  Turk J Urol       Date:  2018-03-01

3.  Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI.

Authors:  Raisa S Pompe; Bieke Kühn-Thomä; Yamini Nagaraj; Valia Veleva; Felix Preisser; Sami-Ramzi Leyh-Bannurah; Markus Graefen; Hartwig Huland; Derya Tilki; Georg Salomon
Journal:  World J Urol       Date:  2018-02-28       Impact factor: 4.226

Review 4.  Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

Authors:  Jeroen Kneppers; Andries M Bergman; Wilbert Zwart
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 5.  A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer.

Authors:  Franklyn De Silva; Jane Alcorn
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

Review 6.  Focal ablation of prostate cancer: four roles for magnetic resonance imaging guidance.

Authors:  Graham Sommer; Donna Bouley; Harcharan Gill; Bruce Daniel; Kim Butts Pauly; Chris Diederich
Journal:  Can J Urol       Date:  2013-04       Impact factor: 1.344

Review 7.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

8.  Correlated diffusion imaging.

Authors:  Alexander Wong; Jeffrey Glaister; Andrew Cameron; Masoom Haider
Journal:  BMC Med Imaging       Date:  2013-08-08       Impact factor: 1.930

Review 9.  The role of focal therapy in the management of localised prostate cancer: a systematic review.

Authors:  Massimo Valerio; Hashim U Ahmed; Mark Emberton; Nathan Lawrentschuk; Massimo Lazzeri; Rodolfo Montironi; Paul L Nguyen; John Trachtenberg; Thomas J Polascik
Journal:  Eur Urol       Date:  2013-06-06       Impact factor: 20.096

10.  Chromatin changes predict recurrence after radical prostatectomy.

Authors:  Tarjei S Hveem; Andreas Kleppe; Ljiljana Vlatkovic; Elin Ersvær; Håkon Wæhre; Birgitte Nielsen; Marte Avranden Kjær; Manohar Pradhan; Rolf Anders Syvertsen; John Arne Nesheim; Knut Liestøl; Fritz Albregtsen; Håvard E Danielsen
Journal:  Br J Cancer       Date:  2016-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.